Why Arena Pharmaceuticals Stock Is Getting Hammered Today

By George BudwellMarketsFool.com

What happened

Continue Reading Below

Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small cap biotech,are down by more than 16% right Tuesday morning as the result of a $69 million public offering that was announced prior to the opening bell. According to the press release, the company also grantedthe underwriters a 30day option to purchase another 9 million shares of common stock.

Image source: Getty Images.

So what

More From Fool.com

While it's never a great idea to tap the public markets for funds when your share price is dangerously close to the Nasdaq minimum bid of $1 per share, Arena didn't have much choice in this case. The company, after all, is facing a likely spike in its quarterly burn rate after deciding to pivot toward its clinical pipeline of early- to mid-stage candidates and move on from its first commercial product, Belviq. Compounding matters, Arena only had about $90 million in cash remaining, according to its last stated cash position.

Now what

Arena's strategy is to try to advance itsexperimentalpulmonary arterial hypertension (PAH) drug, ralinepag, into a late-stage trial in an expedited manner. To do so, the drug needs to hit the mark in its ongoing mid-stage trial that's scheduled to produce a top-line data readout by mid-year. That said,ralinepag's value proposition ultimately revolves around it becoming a so-called "best-in-class" medicine within a rapidly maturing PAH market.

As that's a particularly tall order, especially for a company with rather limited resources like Arena, and investors may want to be extra cautious with this highly volatile biotech stock. That's not to sayralinepag -- or any of the biotech's other clinical candidates -- won't eventually strike gold in their clinical programs, but Arena doesn't have much room left for error at this point.

10 stocks we like better than Arena PharmaceuticalsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Arena Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.